Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/metabolic-engineering-patent-landscape-patent-landscape/ · Patsnap · data cut-off 2026-08-31 · downloaded from the live page
Patent Landscape · Synthetic Biology & BiomanufacturingMetabolic Engineering Patents: Who Leads and Where the Claim Space Is Still Open
- 20.6% concentration at the top. The five leading assignees hold 4,063 of the 19,746 records in scope — a real lead, but not a lock: the other 79.4% is spread across a long tail.
- Filings cooled from a 2018 peak. 987 records in the peak year fell to 371 by 2024, a -52% drop from 2021's 778 — read the last two published years as still filling in, not as a real decline.
- C12N carries three in four records. 75.1% of records touch microorganism and genetic-engineering claims, while therapeutic-activity claims under A61P sit at just 4.6% — a visible gap between pathway engineering and clinical application.
19.7K
Published Records
21%
Top-5 Share of All Records
-52%
Filing Growth 2021→2024
US
Leading Jurisdiction
Filing growth compares 2021 (778 records) with 2024 (371) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 19,746 records in scope (CR5), not by the ranked leaders only.
Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Overview
What the metabolic engineering patent record actually shows
Metabolic engineering patents cluster around a well-worn core: microorganism and genetic-construct claims under C12N, layered with fermentation and enzymatic-synthesis claims under C12P. Together these two classes touch the large majority of the 19,746 records in scope, which tells a filer that pathway-construction claims themselves are dense prior art, not open ground. The interesting variation is downstream: peptide and protein claims, medicinal-preparation claims and plant-breeding claims each cover a much smaller slice, and therapeutic-activity claims narrower still.
That gap between upstream pathway-construction filings and downstream application filings is the first thing worth checking before drafting: a new host-organism or pathway claim is competing against a crowded C12N/C12P base, while a claim tied to a specific therapeutic or agricultural end-use has noticeably more room.
Records by IPC subclass, 2015–2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Metabolic Engineering Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The Data
Filing trend and technology composition
Filing activity, receiving offices and IPC composition for the 19,746 records in scope, drawn from publications dated 2015-01-01 to 2026-08-31.
Filings rose to a 2018 peak, then eased
Annual filings ran from 884 in 2017 to a peak of 987 in 2018. The clearest complete-year comparison is 2021 (778) against 2024 (371), a -52% move. Because publication trails filing by roughly 18 months, 2025 and 2026 figures are undercounts and should not be read as a continuing fall.
C12N and C12P dominate; downstream classes thin out
C12N (microorganisms and genetic engineering) appears in 75.1% of records and C12P (fermentation and enzymatic synthesis) in 47.7%, confirming that pathway-construction claims are the field's structural core. Downstream classes — C07K peptides and proteins at 21.5%, A61K medicinal preparations at 16.4%, A61P therapeutic activity at just 4.6% — carry far less claim density, marking where application-specific claims still have room.
Shares are the percentage of the 19,746 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Metabolic Engineering Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Metabolic Engineering Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about metabolic engineering patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
The most-cited records, and one representative filing
Representative filing
US20230123501A1 — Biosynthesis of commodity chemicals from oil palm empty fruit bunch lignin
NATIONAL UNIVERSITY OF SINGAPORE
Filed by the National University of Singapore, this application engineers an Escherichia coli host with a nine-enzyme, eleven-gene pathway to convert depolymerized oil palm lignin fractions — vanillin, p-coumaric acid, p-hydroxybenzaldehyde, vanillic acid, p-hydroxybenzoic acid and ferulic acid — into β-ketoadipic acid, a precursor to adipic acid and levulinic acid.Published 2023-04-20. It is a useful reference point for how a modern multi-gene pathway claim is structured around a defined feedstock and a named host organism.
Most-cited records in the corpus
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6602684B1 | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity | 4,637 |
| 2 | US5837458A | Methods and compositions for cellular and metabolic engineering | 4,095 |
| 3 | WO1999054342A1 | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity | 3,561 |
| 4 | WO2003011878A2 | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity | 3,385 |
| 5 | US20050123546A1 | Antigen binding molecules with increased Fc receptor binding affinity and effector function | 2,851 |
| 6 | WO2013176772A1 | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcri… | 2,571 |
| 7 | WO1999053050A1 | Methods and means for obtaining modified phenotypes | 2,226 |
| 8 | US20140068797A1 | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcri… | 2,218 |
| 9 | WO1997035966A1 | Methods and compositions for cellular and metabolic engineering | 1,277 |
| 10 | WO2005012515A2 | Novel glyphosate-n-acetyltransferase (GAT) genes | 940 |
Citation counts favour older filings that have had longer to accumulate citations inside this corpus; treat them as a signal of influence on the field, not as a ranking of current commercial relevance. The two most-cited records both concern antibody glycosylation engineering for improved effector function.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Metabolic Engineering Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the numbers mean for a filing decision
Three read-outs from the dataset that matter more for strategy than the headline counts.
Concentration
20.6%
of all 19,746 records held by the top 5 assignees
The lead is real but not a moat
The top 5 assignees combined hold 20.6% of all 19,746 records, and the top 10 combined hold 30.7%. That leaves close to seven in ten records outside the ranked leaders' hands — a long tail of universities, agri-biotech firms and single-filing entrants rather than a market locked up by a handful of players.
Top 5: 4,063 records · Top 10: 6,067 records
Momentum
-52%
filings, 2021 to 2024
Recent-year momentum has cooled across the leaders too
Filings fell from 778 in 2021 to 371 in 2024. That pattern holds inside the leaderboard as well: several of the most active historical filers show sharp year-on-year drops in the latest tracked year, though a single year of publication data understates true filing activity given the reporting lag.
Peak year: 2018 at 987 records
Composition
4.6%
of records carry A61P therapeutic-activity claims
Application-layer claims are thin next to pathway claims
C12N and C12P between them anchor the majority of records, but therapeutic-activity claims under A61P sit at only 4.6% and plant-breeding claims under A01H at 8.6%. A pathway or host-organism claim is entering dense territory; a claim tied to a specific therapeutic or agricultural output is not.
C12N 75.1% · C12P 47.7% · A61P 4.6%
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to metabolic engineering patent landscape, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Metabolic Engineering Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who is filing, and where the collaboration ties sit
The ranking covers 100 companies and research institutions — the full set the data endpoint returns, not a curated top list. Collaboration between assignees is limited: only 10 co-assignee pairs appear across the whole corpus, with the strongest ties running between university and research-institute pairs rather than between commercial competitors.
Leader
1,295
records
The single largest filer sits well ahead of fifth place
The leading assignee holds 1,295 records, against 571 at fifth place and 373 at tenth — a steep drop-off that flattens out through the rest of the ranked 100.
Fifth place: 571 · Tenth place: 373
Collaboration
314
co-filed records, strongest pair
Ties are concentrated among a handful of research institutions
Only 10 co-assignee pairs exist across the dataset. The strongest links pair large university systems with research institutes and named academic collaborators, suggesting joint academic programmes rather than industry consortia are driving the co-filing that does exist.
Second-strongest pair: 312 co-filed records
Momentum
-67% to -100%
YoY range among leading filers
Even the most active historical filers have slowed in the latest tracked year
Several of the most prolific assignees in this dataset show single-digit filing counts and sharp year-on-year declines in the latest year, consistent with the field-wide publication lag rather than a genuine pullback from the technology.
One tracked assignee held flat at 0% YoY
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| Broad Institute, Inc. | 2 | -67% |
| The Regents of the University of California | 1 | -93% |
| Massachusetts Institute of Technology | 1 | -83% |
| Commonwealth Scientific and Industrial Research Organisation (CSIRO) | 1 | 0% |
| Ambrx, Inc. | 0 | -100% |
| The Scripps Research Institute | 0 | — |
| Genomatica, Inc. | 0 | -100% |
| Dow AgroSciences LLC | 0 | — |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Metabolic Engineering Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next
Where to take this from here
The dataset points to specific next questions rather than a single conclusion.
Map a candidate claim against the C12N/C12P core
Before drafting a new pathway or host-organism claim, check it against the density in C12N and C12P — the two classes covering the large majority of records — to see whether the specific enzyme combination or host strain is genuinely distinct.
Explore the IPC breakdownTest white-space branches for freedom to operate
Therapeutic-activity and plant-breeding claims sit at low single-digit to high single-digit shares of the corpus. Running a freedom-to-operate check specifically in those branches, rather than in the crowded pathway-construction core, is likely to be more productive.
Check white space in EurekaWatch the leaders' next filing cycle
Given the 18-month publication lag, the sharp year-on-year drops shown for several leading assignees in the latest tracked year may reverse once 2025-2026 filings finish publishing. Re-check momentum in a future cut before drawing conclusions about a pullback.
Track assignee momentumSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Metabolic Engineering Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions on the metabolic engineering patent landscape
The ranking covers 100 companies and institutions built from 19,746 published records. The single leading assignee holds 1,295 records, well ahead of fifth place at 571 and tenth place at 373, and the top 5 assignees combined account for 20.6% of all records in scope. Beyond the top 10, filing activity spreads across a long tail of universities, agri-biotech firms and single-filing entrants, so no one company controls the field outright.
Filings rose to a peak of 987 records in 2018 and have since eased, with the clearest complete-year comparison — 2021 at 778 versus 2024 at 371 — showing a 52% drop. Because patent publication typically lags filing by around 18 months, the 2025 and 2026 figures in any dataset are undercounts and should not be read as proof the field is still declining. A fuller picture will only be visible once those years finish publishing.
C12N, covering microorganisms and genetic engineering, appears in 75.1% of the 19,746 records in scope, and C12P, covering fermentation and enzymatic synthesis, appears in 47.7%. Downstream application classes are much thinner: C07K peptides and proteins sit at 21.5%, A61K medicinal preparations at 16.4%, and A61P therapeutic activity at only 4.6%. That gap indicates pathway-construction claims are dense prior art while application-specific claims have comparatively more open space.
The clearest gaps sit in the classes with the lowest coverage relative to the C12N/C12P core: therapeutic-activity claims under A61P at 4.6% of records, plant-breeding-related pathway claims under A01H at 8.6%, and enzyme-testing claims under C12Q at 7.7%. Feedstock-specific pathway work, such as lignin-derived commodity chemical synthesis, is also comparatively under-claimed relative to the broad host-organism and pathway-construction filings that dominate the corpus.
The most-cited record in this corpus, US6602684B1, covers glycosylation engineering of antibodies to improve antibody-dependent cellular cytotoxicity, cited 4,637 times, with several other top-cited records covering closely related antibody glycosylation and Fc-receptor binding work. High citation counts inside a searched corpus tend to favour older filings that have had more time to accumulate citations, so they signal historical influence on the field rather than current commercial priority.
Answers are grounded in the same dataset. Derived from a Patsnap search on Metabolic Engineering Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Metabolic Engineering Patent Landscape in depth with Eureka
Go past this page: query the whole metabolic engineering patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.